Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL).

Full DD Report for MDGL

You must become a subscriber to view this report.


Recent News from (NASDAQ: MDGL)

Madrigal Pharmaceuticals misses by $0.03
Madrigal Pharmaceuticals (NASDAQ: MDGL ): Q3 GAAP EPS of -$0.56  misses by $0.03 . More news on: Madrigal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 07:20
Madrigal Pharmaceuticals Reports 2018 Third Quarter Financial Results and Highlights Upcoming Clinical Events
CONSHOHOCKEN, Pa., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2018 financial results and described upcoming clinical events: “Madrigal made important progress thus far in 2018 to advance the development of MGL-31...
Source: GlobeNewswire
Date: November, 06 2018 06:50
The Biotech Bumps
We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...
Source: SeekingAlpha
Date: November, 01 2018 08:00
Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to 10 percent on $60 billion worth of U.S. in response to U.S. tariffs. The Dow Jones Industr...
Source: ACCESSWIRE IA
Date: September, 19 2018 08:00
Breaking Down The NASH Fibrosis Market - Intercept, Genfit Primed For Potential Market Dominance
Over the past year, interest has heated up in the biotech industry about NASH, with analysts estimating market size in 2025 anywhere between $20-35 billion. Positive Phase 2 data readouts for Madrigal (NASDAQ: MDGL ) and Galmed (NASDAQ: GLMD ) caused both stocks to more than double overnight...
Source: SeekingAlpha
Date: September, 10 2018 08:00
Premarket analyst action - healthcare
Theratechnologies ( OTCPK:THERF ) initiated with Sector Perform rating with a C$11 (flat) price target at RBC. More news on: Theratechnologies Inc., Tocagen Inc, Vaccinex, Healthcare stocks news, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 04 2018 09:06
NASH Cirrhosis: The Real NASH Epidemic
Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver...
Source: SeekingAlpha
Date: August, 28 2018 14:19
Viking Therapeutics up 7% ahead of mid-stage data readout on VK2809
Viking Therapeutics ( VKTX +6.5% ) perks up on average volume. Shares have been building a base since its June breakout connected to Madrigal Pharmaceuticals' ( MDGL -0.5% ) successful mid-stage results for NASH candidate MGL-3196, a thyroid hormone receptor-beta agonist. Viking's VK2809...
Source: SeekingAlpha
Date: August, 23 2018 11:32

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14236.38237.28240.19233.09159,404
2018-01-23129.20125.88133.81123.83236,787
2018-01-22124.91129.30131.6999122.939240,742
2018-01-19113.03124.59127.80111.74356,062
2018-01-18105.24111.67113.25104.01230,951

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1428,30854,40152.0358Short
2018-12-1315,93140,68939.1531Short
2018-12-1215,16032,39046.8046Short
2018-12-1121,00439,33453.3991Short
2018-12-1028,22964,83343.5411Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MDGL.


About Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

Logo for Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,860,859,801 - 05/17/2018
  • Issue and Outstanding: 14,250,726 - 05/03/2018

 


Recent Filings from (NASDAQ: MDGL)

Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: August, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 08 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 06 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: June, 05 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 31 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MDGL)

Daily Technical Chart for (NASDAQ: MDGL)


Stay tuned for daily updates and more on (NASDAQ: MDGL)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MDGL)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MDGL is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MDGL and does not buy, sell, or trade any shares of MDGL. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/